Myasthenia gravis pathophysiology

Jump to navigation Jump to search

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis pathophysiology

CDC on Myasthenia gravis pathophysiology

Myasthenia gravis pathophysiology in the news

Blogs on Myasthenia gravis pathophysiology

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Myasthenia gravis is a neuromuscular disease caused by an autoimmune reactions. The main problem in this disease is the abnormal transmission of nerve impulses to muscle fibers in NMJ.[1] In the nerve terminals of alpha motor neurons, there are lots of vesicles containing Ach. When the action potential reaches the synaptic end, voltage gated Ca channels will open and trigger the release of these vesicles. Ach will diffuse into synaptic cleft and binds to AchR. The action of Ach will end with the work of AchE. Ach receptors consist of 5 subunits and are transmembrane proteins. There are other proteins which help AchR clustering and signal transduction including MuSK. It is the receptor of a protein named agrin. When these two bind to each other, the result is maintaining the clustering of AchRs.[2][1][3]

Not all of the MG patients share the same auto antibodies. One of these autoantibodies is antibody against AchR. They will destruct AchR by 3 mechanisms. First they will activate the complement system, second they will increase the degradation af AchR by AB binding and third by blocking AchR’s function.[4] The other type of autoantibody in MG patients are antibody against MsUK protein (muscle-specific receptor tyrosine kinase).[1][5]

References

  1. 1.0 1.1 1.2 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (March 2001). "Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies". Nat. Med. 7 (3): 365–8. doi:10.1038/85520. PMID 11231638.
  2. Horton RM, Manfredi AA, Conti-Tronconi BM (May 1993). "The 'embryonic' gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle". Neurology. 43 (5): 983–6. PMID 7684117.
  3. Ruegg MA, Bixby JL (January 1998). "Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction". Trends Neurosci. 21 (1): 22–7. PMID 9464682.
  4. Sahashi K, Engel AG, Lambert EH, Howard FM (March 1980). "Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis". J. Neuropathol. Exp. Neurol. 39 (2): 160–72. PMID 7373347.
  5. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W (September 2003). "Antibodies in myasthenia gravis and related disorders". Ann. N. Y. Acad. Sci. 998: 324–35. PMID 14592891.

Template:WH Template:WS